This Is MS Multiple Sclerosis Community: Knowledge & Support

For the first time, scientists in Germany's multiple sclerosis competence network have been able to identify an antibody that bonds with the potassium channel KIR4.1. "We found this autoantibody in almost half of the MS patients in our study," explains Bernhard Hemmer, Professor of Neurology at the Klinikum rechts der Isar hospital at Technische Universitaet Muenchen (TUM). The biomarker was not present in healthy patients. The findings could therefore indicate that KIR4.1 is one of the targets of the autoimmune response in MS. Humans and animals without the KIR4.1 channel experience neurological failure and cannot coordinate their movements properly. Furthermore, their bodies do not create sufficient amounts of myelin , a layer of insulation that protects the nerve cells.

KIR4.1 is primarily present in the membrane of glial cells, which are responsible for controlling metabolism in the brain and forming myelin. The neurologists will now be conducting follow-up studies into how KIR4.1 antibodies influence the development of MS. This autoantibody is extremely rare in people with other neurological diseases, making it an important potential diagnostic marker for MS in the future. "This autoantibody could improve diagnosis of MS and help us differentiate it more clearly from other neurological diseases," continues Hemmer. This will also be the focus of further research.

Source: Technische Universitaet Muenchen

Ampyra is a potassium channel blocker, isn't it? Maybe I'm getting this backward but from what I'm reading here it seems Ampyra goes against this discovery.